Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears (IMPACT)

Evaluation of Safety and Efficacy of a Resorbable Collagen Implant in Treatment of High Grade PArtial ThiCkness Tears; A Prospective, Multicenter, Randomized, Control Trial (IMPACT Study)

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears.

Study Overview

• Status: Recruiting
• Conditions: Rotator Cuff Injuries
• Intervention / Treatment: Device: Isolated Bioinductive Repair; Procedure: Completion and Repair

Detailed Description

The primary objective of this study is to evaluate the functional recovery of patients with high grade (>50%) partial thickness tears at 3 months when treated with either Isolated Bioinductive Repair (IBR) or Completion and Repair (CAR).

• Study Type: Interventional
• Enrollment (Estimated): 234
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Alice Kitching; Phone Number: +44 (0) 7590001182; Email: alice.kitching@smith-nephew.com
• Study Contact Backup: Name: Mary Ozokwere; Phone Number: +1 469-560-0727; Email: Mary.Ozokwere@smith-nephew.com

Study Locations

• Australia
  • Victoria
    • Richmond, Victoria, Australia, 3121
      • Recruiting
      • OrthoSport Victoria
      • Principal Investigator: Soong Chua
      • Contact: Haydn Klemm
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2R 2G5
      • Recruiting
      • Access Orthopaedics
      • Contact: Kristie More
      • Principal Investigator: Ian Lo
  • Manitoba
    • Winnipeg, Manitoba, Canada
      • Recruiting
      • Pan Am Clinic
      • Principal Investigator: Jarret Woodmass
      • Contact: Heather Normand
  • Ontario
    • Hamilton, Ontario, Canada
      • Recruiting
      • Research St. Joseph's
      • Principal Investigator: Moin Khan
      • Contact: Danielle Dagher
• Italy
  • Milan, Italy
    • Recruiting
    • IRCCS Istituto Ortopedico Galeazzi,
    • Contact: Vincenzo Guarrella
    • Principal Investigator: Ettore Taverna
  • Roma, Italy
    • Recruiting
    • Fondazione Policlinico Universitario Campus Bio-medico
    • Contact: Giuseppe Longo
    • Principal Investigator: Giuseppe Longo
• Spain
  • Madrid, Spain, 28040
    • Recruiting
    • Hospital Fundación Jiménez Díaz
    • Contact: Cristina Delgado del Cano
    • Principal Investigator: Emilio Calvo
  • Madrid, Spain, 28034
    • Recruiting
    • Hospital Ramon y Cajal
    • Contact: Miguel Angel Ruiz Iban
    • Principal Investigator: Miguel Angel Ruiz Iban
• United Kingdom
  • Bath, United Kingdom
    • Recruiting
    • Sulis Hospital
    • Principal Investigator: Andrew Chambler
  • Bristol, United Kingdom
    • Recruiting
    • North Bristol NHS Trust
    • Contact: Steven Barnfield
    • Principal Investigator: Iain Packham
  • Salford, United Kingdom, M6 8HD
    • Withdrawn
    • Northern Care Alliance NHS Foundation Trust
  • Surrey
    • Chertsey, Surrey, United Kingdom, KT16 0PZ
      • Recruiting
      • Ashford & St Peter's Hospitals NHS Foundation Trust
      • Principal Investigator: Ali Narvani
      • Contact: Timnit Tekie
• United States
  • Georgia
    • Rome, Georgia, United States, 30165
      • Recruiting
      • Harbin Clinic
      • Principal Investigator: Brandon Bushnell
      • Contact: Terri Brannon
  • Illinois
    • Rockford, Illinois, United States, 61107
      • Recruiting
      • OrthoIllinois LTD
      • Principal Investigator: Scott Trenhaile
      • Contact: Catherine Ayala
  • Maryland
    • Baltimore, Maryland, United States, 21215
      • Withdrawn
      • Sinai Hospital Baltimore
  • Ohio
    • Garfield Heights, Ohio, United States, 44125
      • Withdrawn
      • Cleveland Clinic - Sports Health
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • Recruiting
      • University of Pittsburgh
      • Principal Investigator: Albert Lin
      • Contact: Alec Howard
  • Texas
    • Bedford, Texas, United States, 76021
      • Recruiting
      • Texas Orthopedic Specialists
      • Principal Investigator: Howard Harris
      • Contact: Amber Morgan
    • The Woodlands, Texas, United States, 77385
      • Withdrawn
      • Houston Methodist The Woodlands
  • Wisconsin
    • Ashland, Wisconsin, United States, 54806
      • Withdrawn
      • Memorial Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The subject must provide written informed consent.
• Subject is > eighteen (18) years of age (no upper limit).
• Subject has an isolated high-grade (>50% or >6mm) (Ellman grade III) partial thickness tear of supraspinatus or supraspinatus with infraspinatus.
• Subject has failed a minimum of 3 months of conservative management for treatment of partial thickness rotator cuff tear.
• Subject willing and able to make all required study visits.
• Subject able to follow instructions and deemed capable of completing all study questionnaires.

Exclusion Criteria:

• Subjects with insufficient tendon tissue quality for management and protection of the tendon injury using the isolated REGENETEN Bioinductive Implant system.
• Subjects where the prescribed Physical Therapy guidelines stated in the protocol are not suitable for their rehabilitation.
• Subjects with Samilson-Prieto osteoarthritis grade 2 and greater.
• Subjects with current or prior infection of the ipsilateral shoulder.
• Subjects with known hypersensitivity to bovine-derived materials.
• Subjects with known inflammatory arthropathy, history of inflammatory arthropathy, chronic joint disease or chronic pain of upper extremities (shoulder(s), arm(s)).
• Subjects with prior shoulder surgery on index shoulder, including subacromial decompression, biceps tenodesis/tenotomy, and acromioclavicular joint (ACJ) excision/distal clavicle excision (DCE).
• Subjects with a planned surgery on the contra-lateral shoulder within the study period.
• Systemic steroid use (oral, IV) or local steroid injection within 3 months of the date of surgery.
• Subjects with a full thickness rotator cuff tear.
• Subjects with a subscapularis tear requiring repair.
• Subjects requiring a concomitant labral fixation procedure, concomitant surgery for bone defects requiring bone implantation or for superior labral tear from anterior to posterior (SLAP).
• Subjects requiring a concomitant os acromiale fixation procedure.
• Subjects with glenohumeral joint instability (multiple dislocations/subluxations).
• Subjects with condition(s) that contraindicate or complicate outcomes of Isolated Bioinductive Repair or completion and repair e.g., > Hamada 3 rotator cuff arthropathy on X-ray, Goutallier atrophy > Grade 3, proximal humeral fracture or scapular fracture, avascular necrosis of the humeral head.
• Subjects with neurologic conditions effecting either upper extremity.
• Subjects who are unable to tolerate magnetic resonance imaging (MRI), due to psychiatric or medical contraindications.
• Subjects who are pregnant or breast feeding.
• Subjects who are currently involved in any injury litigation relating to the index shoulder.
• Subjects with current workers compensation claim.
• Subjects who are enrolled, or plan to enroll, in another clinical trial during this study that would affect the outcomes of this study.
• Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation.
• Subject who, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, and drug or alcohol abuse.
• Subjects who do not meet the indication or are contraindicated according to specific Smith+Nephew REGENETEN System's Instructions for Use (IFUs).
• Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55.
• Subjects who have participated previously in this clinical trial and who have healed or been withdrawn
• Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Isolated Bioinductive Repair; Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.	Device: Isolated Bioinductive Repair; Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant; Other Names: REGENETEN™ Bioinductive Implant
Active Comparator: Completion and Repair; Surgical treatment of partial-thickness rotator cuff tears using the standard surgical technique 'Completion and Repair'.	Procedure: Completion and Repair; Standard surgical repair using the 'Completion and Repair' technique.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Change from baseline to 3 months post-intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Pre-op, 6 weeks, 3, 6, 12 and 24 months
Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Pre-Op, 3, 6, 12 and 24 months
Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Pre-Op, 6 weeks, 3, 12 and 24 months
EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS & index scores	To assess the subject's health state. The EQ-5D-5L is composed of the EQ- 5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded as single-digit numbers expressing the severity level selected in each dimension. For instance, 'slight problems' (e.g. 'I have slight problems in walking about') is always coded as '2'. The digits for the five dimensions are combined in a 5-digit code. The EQ- 5D-5L index value is derived by using the vendor supplied calculator to convert each 5-digit EQ- 5D-5L profile. The EQ VAS corresponds to a 20 cm vertical, visual analogue scale ranging from 'the best health you can imagine' to 'the worst health you can imagine'. A higher number is a better outcome.	Pre-Op, 3 and 6 weeks, 3, 6, 12 and 24 months
Change in Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Change from Pre-op to 6 weeks, 3, 6, 12 and 24 months
Change in Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Change in Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Change from Pre-Op to 6 weeks, 3, 12 and 24 months
Percent Achieving Minimal Clinically Important Difference (MCID) for Constant-Murley Score	The Constant-Murley Score is a validated assessment of pain and shoulder functionality. The Constant Score is divided into 4 subscales: pain (15 points; VAS score range of 0-15), activities of daily living (20 points; range 0=worst, 5=best), strength (25 points; 1 point given per 0.5 kg of weights raised), and range of motion - forward flexion, external rotation, abduction and internal rotation of the shoulder (40 points; range 0=worst, 10=best). The higher the score, the higher the quality of function.	Pre-Op, 3, 6, 12 and 24 months
Percent Achieving MCID for Western Ontario Rotator Cuff (WORC)	The WORC Index is self-administered, and includes a 5 different domains (physical symptoms, sports and recreation, work, social function, and emotions). Each question uses a visual analog scale (VAS) representing a 100-point scale ranging from 0 to 100. The maximum score is 2100 (worst possible symptoms). Zero (0) represents no symptoms at all. The final score can also be presented as a percentage by subtracting the total from 2100, dividing by 2100, and multiplying by 100. This will give you an overall percentage. The total final WORC Index scores can, therefore, range from 0% (lowest functional status level) to 100% (highest functional status level).	Pre-op, 6 weeks, 3, 6, 12 and 24 months
Percent Achieving MCID for Subjective Shoulder Value (SSV) score	The SSV is defined as a patient's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% (0% to 100% scale with 100% being normal).	Pre-Op, 6 weeks, 3, 12 and 24 months
Patient Satisfaction	Comprise of 2 questions: Overall, I am satisfied with the outcome of my surgery; I would recommend the procedure to a friend. Question rated by the patient with Strongly Agree, Agree, Neither Agree nor Disagree, Disagree, Strongly Disagree.	6 weeks, 3, 6, 12 and 24 months
Pain, Visual analog scale (VAS) Score	Pain is assessed on a 100-point scale ranging from 0 to 100, with zero (0) representing no pain and 100 representing the worst pain imaginable.	Pre-Op, 3 and 6 weeks, 3, 12 and 24 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Sugaya Score	The Sugaya score is classified into 5 categories: Type I to Type V. Type I indicates sufficient thickness with homogenously low intensity. Type II indicates sufficient thickness with partial high intensity. Type III indicates insufficient thickness without discontinuity. Type IV indicates presence of a minor discontinuity, suggesting a small full-thickness tear. Type V indicates the presence of a major discontinuity, suggesting a medium or large full-thickness tear.	12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of percent filling	Percent tissue infil is graded at site of original tear and classified as 0% to < 25%, 25% to < 50%, 50% to < 75%, 75% to < 100% and 100%.	12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via MRI assessment of the signal intensity pattern	The Signal Intensity Pattern will be graded into 3 categories. Type I: Heterogeneous high signal intensity with fluid-like bright foci, Type II: Heterogeneous high signal intensity without fluid-like bright foci, Type III: Heterogeneous or homogeneous low signal intensity.	12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Rotator cuff tendon thickness	Tendon thickness will be measured in millimeters (mm).	12 months
MRI Tendon Findings in subjects with Isolated Bioinductive Repair versus completion via Goutallier classification	The Goutallier classification will be used to classify the fatty infiltration of the rotator cuff. The Goutallier classification ranges from a grade of 0 indicating a completely normal muscles without any fatty streaks to a grade of 4 which indicates that more fat than muscle is present.	12 months
Incidence of Revision Surgery	Number of subjects requiring revision surgery	1, 3 and 6 weeks, 3, 6, 12 and 24 months
Time to return to work	Number of weeks taken to return to work following surgery	Up to 24 months
Time to return to driving	Number of weeks taken to return to driving following surgery	Up to 24 months
Time to return to sports	Number of weeks taken to return to sport following surgery	Up to 24 months
Total operative time	Time expressed in minutes	Inter-operative time
Physical Therapy Utilization	Number visits following index surgery	Up to 24 months
Cumulative days of opioid use	Self-reported opioid use diary completed by the patient on a daily basis, from day 0-14, documenting opioid use. Consumption daily (YES/NO) x14 days, 'Have you taken any opioid medication today for shoulder pain?'	Day 1-14
Duration of shoulder immobilization following index surgery	Number of days	1, 3 and 6 weeks, 3 months

Collaborators and Investigators

• Sponsor: Smith & Nephew, Inc.
• Investigators: Study Chair: Laura Mills, Smith & Nephew, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2022
• Primary Completion (Estimated): August 15, 2026
• Study Completion (Estimated): June 30, 2028

Study Registration Dates

• First Submitted: June 29, 2022
• First Submitted That Met QC Criteria: June 29, 2022
• First Posted (Actual): July 6, 2022

Study Record Updates

• Last Update Posted (Actual): January 15, 2026
• Last Update Submitted That Met QC Criteria: January 14, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: REGENETEN Bioinductive Implant System; Rotator cuff tear; High grade partial thickness tears
• Additional Relevant MeSH Terms: Shoulder Injuries; Wounds and Injuries; Rupture; Tendon Injuries; Rotator Cuff Injuries; Biological Phenomena; Regeneration; Wound Healing
• Other Study ID Numbers: REGENETEN.2021.04

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No